Belgia - Inggris - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

air liquide santé international s.a. - nitric oxide 800 ppm mol/mol - medicinal gas, compressed - 800 ppm mole/mole - nitric oxide - nitric oxide

Belgia - Inggris - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

air liquide santé international s.a. - nitric oxide 450 ppm mol/mol - medicinal gas, compressed - 450 ppm mole/mole - nitric oxide - nitric oxide

Israel - Inggris - Ministry of Health

vertex pharmaceuticals (u.k) limited, israel - ivacaftor; tezacaftor - film coated tablets - ivacaftor 150 mg; tezacaftor 100 mg - ivacaftor and tezacaftor - symdeko is a combination of tezacaftor and ivacaftor, indicated for the treatment of patients with cystic fibrosis (cf) aged 12 years and older who are homozygous for the f508del mutation or who have at least one mutation in the cystic fibrosis transmembrane conductance regulator (cftr) gene that is responsive to tezacaftor/ivacaftor based on in vitro data and/or clinical evidence.if the patient’s genotype is unknown, a health authority cleared cf mutation test should be used to detect the presence of a cftr mutation followed by verification with bi-directional sequencing when recommended by the mutation test instructions for use.

Israel - Inggris - Ministry of Health

vertex pharmaceuticals (u.k) limited, israel - ivacaftor; tezacaftor - film coated tablets - ivacaftor 150 mg; tezacaftor 100 mg - ivacaftor and tezacaftor - symdeko is a combination of tezacaftor and ivacaftor, indicated for the treatment of patients with cystic fibrosis (cf) aged 12 years and older who are homozygous for the f508del mutation or who have at least one mutation in the cystic fibrosis transmembrane conductance regulator (cftr) gene that is responsive to tezacaftor/ivacaftor based on in vitro data and/or clinical evidence.if the patient’s genotype is unknown, a health authority cleared cf mutation test should be used to detect the presence of a cftr mutation followed by verification with bi-directional sequencing when recommended by the mutation test instructions for use.

Uni Eropa - Inggris - EMA (European Medicines Agency)

vertex pharmaceuticals (ireland) limited - ivacaftor, tezacaftor, elexacaftor - cystic fibrosis - other respiratory system products - kaftrio is indicated in a combination regimen with ivacaftor for the treatment of cystic fibrosis (cf) in patients aged 6 years and older who have at least one f508del mutation in the cystic fibrosis transmembrane conductance regulator (cftr) gene.

Israel - Inggris - Ministry of Health

vertex pharmaceuticals (u.k) limited, israel - elexacaftor; ivacaftor; ivacaftor; tezacaftor - film coated tablets - ivacaftor 75 mg; tezacaftor 50 mg; elexacaftor 100 mg; ivacaftor 150 mg - ivacaftor, tezacaftor and elexacaftor - trikafta is indicated for the treatment of cystic fibrosis (cf) in patients aged 12 years and older who have at least one f508del mutation in the cftr gene or a mutation in the cftr gene that is responsive based on in vitro data.

Israel - Inggris - Ministry of Health

vertex pharmaceuticals (u.k) limited, israel - ivacaftor; ivacaftor; tezacaftor - film coated tablets - ivacaftor 75 mg; tezacaftor 50 mg; ivacaftor 75 mg - ivacaftor and tezacaftor - symdeko is a combination of tezacaftor and ivacaftor, indicated for the treatment of patients with cystic fibrosis (cf) age 6 years and older who are homozygous for the f508del mutation or who have at least one mutation in the cystic fibrosis transmembrane conductance regulator (cftr) gene that is responsive to tezacaftor/ivacaftor based on in vitro data and/or clinical evidence.if the patient’s genotype is unknown, a health authority cleared cf mutation test should be used to detect the presence of a cftr mutation followed by verification with bi-directional sequencing when recommended by the mutation test instructions for use.

Israel - Inggris - Ministry of Health

oxygen & argon works,oxygen centre ltd - nitric oxide - gas - nitric oxide 800 ppm - nitric oxide - noxap 800 ppm, in conjunction with ventilatory support and other appropriate active substances, is indicated: •for the treatment of newborn infants ≥34 weeks gestation with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension, in order to improve oxygenation and to reduce the need for extracorporeal membrane oxygenation. •as part of the treatment of peri- and post-operative pulmonary hypertension in adults and newborn infants, infants and toddlers, children and adolescents, ages 0-17 years in conjunction to heart surgery, in order to selectively decrease pulmonary arterial pressure and improve right ventricular function and oxygenation.

Israel - Inggris - Ministry of Health

rafa laboratories ltd - petasins - tablets - petasins 8 mg - for the treatment of symptoms of allergic rhinitis (hay-fever) as well as related symptoms in eyes, nose and throat.

Armenia - Inggris - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

lek pharmaceuticals d.d. - lyophilized bacterial lysate - capsules hard - 7mg